A randomised trial comparing 18F-fluorocholine positron emission tomography/computed tomography (FCH-PET/CT) with Conventional Imaging (computed tomography and whole-body bone scan) with respect to their first-line utility in the staging or restaging of patients with prostate cancer.

Peter MacCallum Cancer Centre0 个研究点目标入组 100 人开始时间: 2008年12月17日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•Biopsy-proven prostate cancer;
•Age = 18 years;
•Written informed consent has been provided.
•Newly-diagnosed prostate cancer (Staging Population):
•Patient has not undergone any form of treatment for his disease;
•Non-low risk disease. He must have at least one of the following features: prostate specific antigen (PSA) = 10.0 ng/ml within 8 weeks prior to randomisation; Gleason score = 7; clinical stage = T2b.
•Suspected recurrent prostate cancer (Restaging Population):
•Patient has undergone local radical treatment;
•Within the 8 weeks prior to randomisation, the PSA level must be = 0.5 ng/ml and rising (post-operatively) or a PSA level of 2 ng/mL or more above the nadir PSA level (post-radiotherapy).

•Participant has undergone, within 8 weeks prior randomisation, a diagnostic imaging(DI) procedure for the staging (N-staging or M-staging) or restaging of his prostate cancer;
•A history of other active malignancy within the last 5 years, with exception of non-melanoma skin cancer;
•Presently having androgen deprivation therapy started less than 6 months ago;
•Where radical treatment of the patient would not be contemplated on the basis of limited expected lifespan due to comorbid conditions.

发起方

Peter MacCallum Cancer Centre